According to investing7's report on July 31, the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for Cytisinicline, a treatment for nicotine e-cigarette cessation. This medication is developed by the American pharmaceutical company Achieve Life Sciences. If approved, it would be the first drug specifically designed for nicotine e-cigarette cessation. It is important to note that Cytisinicline is currently an experimental product and has not received any approval for use by the FDA in the United States.
Golden Chrysanthemum Alkaloid is a plant-based alkaloid with high affinity for binding to nicotine acetylcholine receptors. By interacting with nicotine receptors in the brain, it reduces the severity of withdrawal symptoms and decreases the reward and satisfaction associated with nicotine products, aiding in the treatment of nicotine addiction resulting from smoking and e-cigarette cessation.
According to sources, the company's ORCA-V1 phase II clinical trial compared the effects of lobeline and a placebo on 160 adult e-cigarette users. The experiment showed that participants treated with lobeline were 2.6 times more likely to successfully quit smoking compared to those using the placebo. Achieve Corporation plans to hold a phase II final meeting with the FDA's multidisciplinary team by the end of this year to discuss the next steps.
Data shows that over 11 million adults in the United States use e-cigarettes, with approximately 2.1 million middle and high school students also using them. Currently, the FDA has not approved any specific treatment methods to help individuals quit nicotine e-cigarettes.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
